RxDoctor Payments DataLook up a doctor →

Lana Schmidt, MD

Dermatology · Effingham, ILNPI 1245260082

Payments from drug & device makers

$1,300,979in general payments, 2019–2025

Across 1,780 payments — averaging $730.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$253K
  • Lilly USA, LLC$247K
  • Amgen$209K
  • E.r. Squibb & Sons, L.L.C.$104K
  • Janssen Scientific Affairs, LLC$98K
  • Johnson & Johnson$89K
  • plus $302K from 15 others

What the payments were for

  • Consulting fees$79,9276%
  • Speaking & faculty fees$1,130,63587%
  • Travel & lodging$61,6355%
  • Food & beverage$28,0582%
  • Education$7250%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,300,979 in reported general payments places this provider in the 95th percentile of 606 dermatology providers in Illinois.

See all dermatology providers in Illinois

Medicare billing

Part B allowed, 2024
$320,337
Medicare patients
1,287
Services billed
8,498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast49$233,694
TremfyaGuselkumab17$232,616
Humira(Cf) PenAdalimumab14$183,916
RinvoqUpadacitinib23$144,200
Dupixent SyringeDupilumab27$134,819
Taltz AutoinjectorIxekizumab16$105,226
VtamaTapinarof13$17,733
Fluorouracil127$10,327
Minoxidil369$3,068
Acitretin25$2,892
Minocycline Hcl189$2,650
Metronidazole29$2,342
Doxycycline Hyclate100$2,252
Imiquimod114$1,917
Clobetasol Propionate35$1,852

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$208,963$233,69449 claims
Johnson & JohnsonTremfya$88,707$232,61617 claims
AbbVieRinvoq$252,602$144,20023 claims
Dermavant Sciences, Inc.Vtama$80,879$17,73313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 606 dermatology providers in Illinois.

Other dermatology in Effingham

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →